Drugs

Themenbereich / / Drugs


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Animal Generic Drug Market Current Trends, Analysis, and Growth Factors

The global animal generic drug market has been estimated to foresee an explosive growth by the year 2028. The growing competition in the pet medicine industry is fueling the penetration of animal generic drugs. However, generic drugs have been attributed to have lower profit margins for manufacturers and is therefore, hindering the market growth. Several national distributors have started to produce generic drugs under private label, which is propelling market expansion. Based on type, animal generic drug market has been segmented into Pharmaceuticals, Medicinal Feed Additives, and Biologic ...

02.12.2019

Vitamin and Provitamin Market Growth Opportunities and Competitive Landscape

Global vitamin and provitamin market is expected to grow at a significant CAGR in the upcoming period as the scope and its applications are rising enormously across the globe. A provitamin also termed as previtamin, is a substance that may be converted into a vitamin within the body. The provitamin B5 may be converted in the body to vitamin B5 (pantothenic acid). Beta-carotene is a provitamin composed of two retinyl groups. It is broken down in the mucosa of the small intestine by beta-carotene dioxygenase to retinal, a form of vitamin A. The factors that are playing a major role in the growt ...

06.11.2019

Acne Drugs Market Comprehensive Industry Analysis and Growth Driving Factors

Global Acne Drugs Market expected to observe a rising CAGR in forthcoming period owing to the increasing skin disorders, unhealthy lifestyle, and emergence of biologics. Acne is a common skin disorder that is prevalent in all age groups, especially in adolescents and premature adults. Acne drugs play an important role to reduce inflammation, speed up skin cell turnover, and control bacterial infection. Growing awareness among young population regarding acne and increasing number of manufacturers developing advance drugs for acne treatment drives the market growth. However, side effects caused ...

04.11.2019

Prenatal Vitamin Supplements Market Analysis, Growth, and Forecast Report

The global prenatal vitamin supplements market is expected to display higher growth rate over the next seven years. Rapid surge in prenatal vitamin supplements industry is credited to the rising demand of prenatal vitamin supplements and its capability to reduce the risk associated with congenital disabilities in infants. Prenatal vitamin supplements acts as a natural source of vital supplement, which is highly required during the pregnancy. The recent technological advancement in the pharmaceutical & medicine sector has led to development of high-quality prenatal vitamin supplements that ...

17.10.2019

Vitamin K3 Market Current Trends, Growth Opportunities, and Analysis Report

Global vitamin K3 market is anticipated to witness an exponential growth in the forecast period. Vitamin K3 is also known as ements. In addition, change in consumer lifestyle along with an increase in beauty products usage and increasing health awareness among the population are likely to propel the vitamin K3 market in the forthcoming period. On the other hand, stringent rules set by government establishments such as FDA and low product penetration in emerging countries are anticipated to hinder the market growth in the future. However, technological progressions in vitamin delivery systems ...

03.10.2019

Dry Mouth Relief Market Growth Scenario, Future Trends, and Business Analysis

The global dry mouth relief market is expected to display higher growth rate in the upcoming years. Rapid surge in the market is credited to the prevalence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma, and rising air pollution levels, particularly in developing economies across the globe. Rising efforts by local governments to provide low cost healthcare services and growing awareness levels are expected to drive the growth of dry mouth relief market over the forecast period. Rapid surge for demand for dry mouth relief products is credited to the recent te ...

03.10.2019

Insulin Market Development Trends, Business Analysis, and Growth Rate

The global insulin market is subject to witness a substantial growth due to the increasing incidence of diabetes, growing geriatric population and changing lifestyle across the globe. Varying food patterns, easy availability and decline in cost of the products are some of the major factors driving market demand for insulin, in the recent years. In addition, advent of pen devices as well as the safety pen needles for efficient transmission of insulin in the human body are expected fuel market growth over the forecast period. Development of innovative techniques and novel products by industry p ...

13.09.2019

Rising Opportunities in the Emerging Industry to Boost the Growth of the Therapeutic Drug Monitoring Market

According to the new market research report   Global Forecast to 2023 The growth of this market is majorly driven by the rising number of organ transplant procedures and the use of TDM in traditional anticancer therapies. Based on product, the consumables segment is expected to grow at the highest CAGR during the forecast period On the basis of product, the global therapeutic drug monitoring market is segmented into consumables and equipment. The consumables segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the r ...

14.06.2019

PAREXEL Navigates China''s Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service

BOSTON, October 31, 2018 - PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that the Company has launched a new China Advisory Service to help global biopharmaceutical companies participate in the growing, yet complex market opportunity within China. The offering leverages PAREXEL''s deep experience with and knowledge of the Chinese biopharmaceutical landscape to help companies navigate all aspects of the country''s drug development process. This includes overall strategy, agency engagement and agreements, early de ...

31.10.2018

Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team - Company reports strong growth.

Vienna, July 31, 2018. Vienna based Marinomed Biotech AG (Marinomed) strengthens its management team with the appointment of Pascal Schmidt as Chief Financial Officer (CFO) from August 1, 2018. This addition to the leadership team marks another important milestone in the further growth trajectory of the biopharmaceutical firm which develops innovative technology platforms. Pascal Schmidt, 45 years old, holds a degree in business administration from the University of Bayreuth and has more than 20 years&A. Most recently, he held the position of managing director at Raymond James Financia ...

31.07.2018

Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner

LAVAL, QUEBEC -- (Marketwired) -- 11/20/17 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the company recently entered into a non-binding term sheet with a leading China-based pharmaceutical company. Completion of the transaction is subject to further negotiation and execution of a definitive agreement, which once signed would grant an exclusive license to the C ...

20.11.2017

CanniMed to Acquire Up Cannabis Inc. (Newstrike Resources Ltd. - TSX-V: HIP) to Create a Premier Global Cannabis Company

SASKATOON, SASKATCHEWAN and OAKVILLE, ONTARIO -- (Marketwired) -- 11/17/17 -- Editors Note: A photo for this release is available on the Canadian Press picture wire via Marketwired.Transaction HighlightsCanniMed Therapeutics Inc. (TSX: CMED) ("CanniMed") and Newstrike Resources Ltd. (TSX VENTURE: HIP) ("Newstrike") are pleased to announce that they have reached a definitive agreement (the "Arrangement Agreement") pursuant to which CanniMed will acquire all of the outstanding shares of Newstrike (the "Arrangement"), parent company of Up Cannabis Inc. (&q ...

17.11.2017

Omni Health, Inc. Releases Letter to Shareholders

MIAMI, FL -- (Marketwired) -- 11/14/17 -- , (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:Dear Shareholders,As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities fo ...

14.11.2017

Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress

BUFFALO, NY -- (Marketwired) -- 11/14/17 -- (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2017.Cleveland BioLabs reported a net loss of $(1.3) million, excluding minority interests, for the third quarter of 2017, or $(0.11) per share, compared to a net gain, excluding minority interests, of $1.1 million, or $0.10 per share, for the same period in 2016. The increase in net loss was primarily due to an increase in the non-cash adjustment to our warrant liabilities and decreased revenues and expenses due to the completion of o ...

14.11.2017

Acasti Pharma Reports Second Quarter FY 2018 Financial Results

LAVAL, QUEBEC -- (Marketwired) -- 11/13/17 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced its operating and financial results for the quarter ended September 30, 2017, which is the second quarter of Acasti''s fiscal year 2018. All amounts are in Canadian dollars."Acasti met several key milestones in the second quarter, advancing our Phase 3 clinical p ...

13.11.2017

Knight Reports Third Quarter 2017 Results

MONTREAL, QUEBEC -- (Marketwired) -- 11/09/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2017. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.Q3 2017 HighlightsSubsequent Events"This past quarter our team was focused on advancing our product pipeline and evaluating opportunities to build our portfolio of innovative pharmaceuticals," said Jonathan Ross Good ...

09.11.2017

Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program

LAVAL, QUEBEC -- (Marketwired) -- 11/07/17 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Dariush Mozaffarian, M.D., Dr.P.H. has agreed to serve as Acasti''s principal investigator to oversee the Phase 3 development program of CaPre. Dr. Mozaffarian is a renowned researcher whose widely published work focuses on how diets such as those rich in omega-3 ...

07.11.2017

Notice of Knight Therapeutics'' Third Quarter 2017 Results Conference Call

MONTREAL, QUEBEC -- (Marketwired) -- 11/02/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, will release its third quarter 2017 financial results on Thursday, November 9, 2017 prior to the market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.Date: Thursday, November 9, 2017Time: 8:30 a.m. ESTTelephone: 1-877-223-4471 or 647-788-4922Webcast: orThis is a listen-only audio webcast. Media Player is required to lis ...

02.11.2017

Knight Announces Changing of the Finance Guard

MONTREAL, QUEBEC -- (Marketwired) -- 10/10/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017 in order to pursue other opportunities. Mr. Kadanoff served valiantly in this position since Knight became a publicly listed company in February 2014.Effective immediately, Samira Sakhia, President of Knight, will assume the additional responsibility of CFO. Prior to joining Knight, Ms. Sakhia served as CFO of Paladin Labs Inc. for 14 years.Jonatha ...

10.10.2017

Knight Increases Ownership in Crescita

MONTREAL, QUEBEC -- (Marketwired) -- 10/10/17 -- Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (TSX: GUD) ("Knight") announced today an increase in its ownership of Crescita Therapeutics Inc. ("Crescita").On October 6, 2017, Knight acquired 566,471 common shares of Crescita, representing 4.0% of the issued and outstanding common shares of Crescita, pursuant to a share transfer agreement entered into on August 31, 2016 by and between Knight and Mr. Gregory Orleski (the "Agreement"). Pursuant to the Agreement, K ...

10.10.2017


Page 1 from 64:  1 2  3  4  5  .. » 64





All members: 9 432
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 72


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.